Kamada Completes Step in Study of Inhaled AAT with Bronchiectasis Patients
March 19, 2009
NESS ZIONA, Israel—(BUSINESS WIRE)—Kamada, a bio-pharmaceutical company (http://www.kamada.com) engaged in the development, manufacturing and marketing of specialty life-saving therapeutics, announced today that it has completed the last patient visit in a Phase II bronchiectasis study with its Inhaled Alpha-1 Antitrypsin (AAT), delivered via an optimized Investigational eFlow Nebulizer System (PARI Pharma GmbH). Preliminary results indicate that the product continues to demonstrate a good safety profile; final analysis of airway inflammation and secondary endpoints is expected to be available by mid-year.
David Tsur, Kamada’s CEO expressed enthusiasm at the advancement of Inhaled AAT for the treatment of bronchiectasis. “This is another milestone for Kamada in the development of Inhaled AAT. Bronchiectasis affects approximately 600,000 people world-wide1 and we believe our novel approach, which could impact the underlying inflammatory processes, may considerably improve the quality of life of these patients. We look forward to receiving the final data from this study in the coming months,” said Mr. Tsur.
According to Pnina Strauss, Kamada’s Clinical Trials and IP Manager, “This is the third Phase II clinical trial we have conducted with Inhaled AAT and we continue to observe a very promising safety profile.”
(To continue reading the article, click here.)